X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ORCHID PHARMA LTD - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ORCHID PHARMA LTD ASTRAZENECA PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 176.6 0.1 125,791.4% View Chart
P/BV x 26.8 0.2 16,129.7% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
ORCHID PHARMA LTD
Sep-13
ASTRAZENECA PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,285194 662.4%   
Low Rs63435 1,811.4%   
Sales per share (Unadj.) Rs189.6276.5 68.6%  
Earnings per share (Unadj.) Rs-0.2-79.2 0.3%  
Cash flow per share (Unadj.) Rs3.8-43.5 -8.8%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.653.9 127.3%  
Shares outstanding (eoy) m25.0070.45 35.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.10.4 1,222.0%   
Avg P/E ratio x-4,712.7-1.4 326,015.5%  
P/CF ratio (eoy) x249.6-2.6 -9,471.3%  
Price / Book Value ratio x14.02.1 658.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9888,067 297.4%   
No. of employees `0001.62.8 55.7%   
Total wages/salary Rs m1,6052,527 63.5%   
Avg. sales/employee Rs Th3,040.26,956.1 43.7%   
Avg. wages/employee Rs Th1,029.2902.5 114.0%   
Avg. net profit/employee Rs Th-3.3-1,993.0 0.2%   
INCOME DATA
Net Sales Rs m4,74019,477 24.3%  
Other income Rs m92407 22.6%   
Total revenues Rs m4,83219,884 24.3%   
Gross profit Rs m-1301,103 -11.8%  
Depreciation Rs m1012,519 4.0%   
Interest Rs m05,227 0.0%   
Profit before tax Rs m-139-6,236 2.2%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m139511 27.2%   
Tax Rs m5-125 -4.1%   
Profit after tax Rs m-5-5,580 0.1%  
Gross profit margin %-2.75.7 -48.4%  
Effective tax rate %-3.72.0 -182.5%   
Net profit margin %-0.1-28.7 0.4%  
BALANCE SHEET DATA
Current assets Rs m2,72611,014 24.8%   
Current liabilities Rs m2,43532,060 7.6%   
Net working cap to sales %6.1-108.1 -5.7%  
Current ratio x1.10.3 325.9%  
Inventory Days Days7495 77.7%  
Debtors Days Days4134 121.5%  
Net fixed assets Rs m1,03529,440 3.5%   
Share capital Rs m50705 7.1%   
"Free" reserves Rs m9422,043 46.1%   
Net worth Rs m1,7163,800 45.2%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m4,15646,510 8.9%  
Interest coverage xNM-0.2-  
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x1.10.4 272.3%   
Return on assets %-0.1-0.8 16.1%  
Return on equity %-0.3-146.9 0.2%  
Return on capital %0-3.7 0.0%  
Exports to sales %5.737.9 15.1%   
Imports to sales %6.522.6 28.6%   
Exports (fob) Rs m2707,378 3.7%   
Imports (cif) Rs m3064,406 7.0%   
Fx inflow Rs m3757,513 5.0%   
Fx outflow Rs m4705,649 8.3%   
Net fx Rs m-961,865 -5.1%   
CASH FLOW
From Operations Rs m-81,682 -0.5%  
From Investments Rs m-146-9,860 1.5%  
From Financial Activity Rs m8626,644 13.0%  
Net Cashflow Rs m709-1,535 -46.2%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.6 6.5%  
FIIs % 15.7 3.3 475.8%  
ADR/GDR % 0.0 4.6 -  
Free float % 9.1 55.3 16.5%  
Shareholders   12,856 84,811 15.2%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  SHASUN PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS